Bendectin and Birth Defects: Hopefully, the Final Chapter

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 67, Issue 2, 2003, Pages 79-87

  Brent, Robert ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENDECTIN; DICYCLOVERINE; DOXYLAMINE; MECLOZINE; PHENOTHIAZINE DERIVATIVE; PYRIDOXINE;

BIRTH DEFECT; CLINICAL FEATURE; DRUG MARKETING; DRUG WITHDRAWAL; ECOLOGY; ENVIRONMENTAL EXPOSURE; HUMAN; LAW SUIT; NAUSEA; NOTE; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; TERATOGENESIS; TOXICOKINETICS; VOMITING; ADULT; ANIMAL; CASE CONTROL STUDY; CONGENITAL MALFORMATION; DRUG APPROVAL; DRUG COMBINATION; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; FEMALE; FETUS; FOOD AND DRUG ADMINISTRATION; LEGAL LIABILITY; NEWBORN; PREGNANCY COMPLICATION; SAFETY; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ANTIEMETICS; CASE-CONTROL STUDIES; DOXYLAMINE; DRUG APPROVAL; DRUG COMBINATIONS; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; LIABILITY, LEGAL; NAUSEA; PREGNANCY; PREGNANCY COMPLICATIONS; PYRIDOXINE; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VOMITING;

EID: 0141889512     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.10021     Document Type: Note

References (120)

1. Anonymous. Bendectin production ends. 1983. Sci News (Washington) 123:389.
2. Aselton P, Jick H. 1983. Additional follow-up of congenital limb disorders in relations to Bendectin use. JAMA 250:33-34.
3. Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, Torrance GW. 2002. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol 186(Suppl):220-227.
4. Bauersachs J, Fraccarollo D, Widder J, Ertl G. 1999. Correction of endothelial dysfunction in rats with chronic myocardial infarction by treatment with endothelin receptor antagonists. JACC 33:179
5. Bendectin Litigation. 1984. Civil No. MDL 486, United States District Court for the Southern District of Ohio, July 14, 1984.
6. Black FO. 2002. Maternal susceptibility to nausea and vomiting of pregnancy: Is the vestibular system involved? Am J Obstet Gynecol 186(Suppl):204-209.
7. Blum J, et al. vs. Merrell Dow Pharmaceuticals, Inc. 1999. In the Supreme Court of Pennsylvania (Eastern District) No. 1 e.d. Appeal Docket 1999.
8. Bouwes-Bavinck JN, Weaver DD. 1986. Subclavian artery supply disruption sequence: hypothesis of a vascular etiology for Poland, Klippel-Feil and Moebius anomalies. Am J Med Genet 23:903-918.
9. Bracken MB, Berg A. 1983. Bendectin (Debendox) and congenital diaphramatic hernia. Lancet 1:586.
10. Bracken MB, Holford TR. 1981. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58:336.
11. Braun AG, Buckner CA, Emerson DJ, Nichinson BB. 1982. Quantitative correspondence between the in vivo and in vitro activity of teratogenic agents. Proc Natl Acad Sci USA 79:2056-2060.
12. Brent RL. 1967. Medicolegal aspects of teratology. J Pediatr 71:288-298.
13. Brent RL. 1968. Evaluation of developmental effects and teratogenicity of drugs. In: report of the Fifty-Eighth Ross Conference on Pediatric Research. pp. 78-82.
14. Brent RL. 1977. Litigation-produced pain, disease and suffering: an experience with congenital malformation lawsuits. Teratology 16:1-14.
15. Brent RL. 1978. Method of evaluating alleged human teratogens. Teratology 17:183.
16. Brent RL. 1982. The irresponsible expert witness: a failure of biomedical graduate education and professional accountability. Pediatrics 70:754-762.
17. Brent RL. 1983. The Bendectin saga: another American tragedy (Brent '80). Teratology 27:283-286.
18. Brent RL. 1985a. Editorial comments on "Teratogen Update: Bendectin." Teratology 31:429-430.
19. Brent RL. 1985b. Bendectin and interventricular septal defects. Teratology 32:317-318.
20. Brent RL. 1985c. Methods of evaluating and alleged teratogenicity of environmental agents. In: Marois M, editor. Prevention of physical and mental congenital defects. Part C: basic and medical science, education and future strategies. New York: Alan R. Liss, Inc. pp. 191-195.
21. Brent RL. 1986. Methods of evaluating the alleged teratogenicity of environmental agents. In: Sever JL, Brent RL, editors. Teratogen update: environmentally induced birth defect risks. New York: Alan R. Liss. pp. 199-201.
22. Brent RL. 1987. Malpractice experience and issues. In: medical-legal issues in pediatrics, report of the Eighteenth Ross Roundtable on Critical Approaches to Common Pediatric Problems in collaboration with the Ambulatory Pediatric Association. Columbus, Ohio. pp. 20-25.
23. Brent RL. 1989a. Kudos to the Food and Drug Administration: reversal of the package insert warning for birth defects for oral contraceptives. Teratology 39:93-94.
24. Brent RL. 1989b. Improving the quality of expert witness testimony. Pediatrics 82:511-513 1988. Reprinted in Teratology as an editorial. Teratology 39:215-219.
25. Brent RL. 1989b. Improving the quality of expert witness testimony. Pediatrics 82:511-513 1988. Reprinted in Teratology as an editorial. Teratology 39:215-219.
26. Brent RL. 1992a. Awards and recognition in science: a distortion of reality. The Scientist 6:12.
27. Brent RL. 1992b. The changing role and responsibilities of chairmen in clinical academic departments: the transition from autocracy. Pediatrics 90:50-57.
28. Brent RL. 1993. A systematic evaluation of the reproductive risks of caffeine. Presented at: Seventh International Caffeine Workshop; Santorini, Greece.
29. Brent RL. 1995a. Bendectin: Review of the medical literature of a comprehensively studied human non-teratogen and the most prevalent tortogen-litigen. Reprod Toxicol 9:337-349.
30. Brent RL. 1995b. Bringing scholarship to the courtroom: the Daubert decision and its impact on the Teratology Society. Teratology 52:247-251.
31. Brent RL. 1995c. Bringing scholarship to the courtroom: the Daubert decision. The Scientist 9:11.
32. Brent RL. 1997. Review of the scientific literature pertaining to the reproductive toxicity of Bendectin. In: Faigman DL, Kaye DH, Saks MJ, Sanders J, editors. Modern scientific evidence: the law and science of expert testimony. vol 2. St. Paul, MN: West Publishing Group. pp. 373-393.
33. Brent RL. 1999a. Reproductive and teratologic effects of low frequency electromagnetic fields: a review of in vivo and in vitro studies using animal models. Teratology 59:261-286.
34. Brent RL. 1999b. Response to Dr. Stuart Newman's commentary on an article entitled, "Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litogen." Reprod Toxicol 13:245-253.
35. Brent RL. 2002. Medical, social and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol 186(Suppl):262-266.
36. Brent RL, Gordon WE, Bennett WR, Beckman DA. 1993. Reproductive and teratologic effects of electromagnetic fields. Reprod Toxicol 7:535-580.
37. Brent RL, Jensh RP, Beckman DA. 1991. Medical sonography: reproductive effects and risks. Teratology 44:123-146.
38. Brent RL, Koren G, Scialli A, Zimmerman E. 1989. Report on the safety of Bendectin/Diclectin for use in the management of nausea and vomiting of pregnancy. Health Protection Branch, Canada, November 8, 1989.
39. Brill CB, Hsu LYF, Hirsachhorn K. 1972. The syndrome of ectrodactyly, ectodermal dysplasia and cleft lip and palate: Report of a family demonstrating dominant inheritance pattern. Clin Genet 3:295-302.
40. Buckwalter JG, Simpson SW. 2002. Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. Am J Obstet Gynecol 186(Suppl):210-214.
41. Budroe JD, Shaddock JG, Casciano DA. 1984. A study of the potential genotoxicity of methapirilene and related antihistamines using hepatocyte/DNA repair assay. Mutat Res 135:131-137.
42. Bujdoso G, Lenz W. 1980. Monodactylous splithand-splitfoot: a malformation occurring in three distinct genetic types. Eur J Pediatr 133:207-215.
43. Bumpus FM. 1977. Mechanism and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor. Fed Proc 36:2128-2132.
44. Bunde CA, Bowles DM. 1963. A technique for controlled survey of case records. Curr Ther Res 5:245-248.
45. Bunde CA, Leyland HM. 1965. A controlled retrospective survey in evaluation of teratogenicity. J New Drugs 5:193-198.
46. Christian MS, Brent RL. 2001. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 64:51-78.
47. Clarke M, Clayton DG. 1981. Safety of Debendox. Lancet 1:659-660.
48. Cobben JM, Robinson PH, van Essen AJ, van der Wiel HL, ten Kate LP. 1989. Poland anomaly in mother and daughter. Am J Med Genet 33:519-521.
49. Cockayne EA. 1936. Cleft palate-lip, hare lip, dacryocystitis, and cleft hand and food. Biometrika 28:60-63.
50. Congenital Malformation Surveillance Bulletin. 1993. Teratology 48:545-709.
51. Cordero JF, Oakley GP, Greenberg F, James LM, Levy M. 1981. Is Bendectin a teratogen? JAMA 245:2307-2310.
52. Corfman PA. 1988. Labeling guidance for combination oral contraceptives. Contraception 37:433-455.
53. Correy JF, Newman NM. 1981. Debendox and limb reduction deformities. Med J Aust 1:417-418.
54. Daubert vs. Merrell Dow Pharmaceuticals, Inc. 1989. 727 F. Supp. 570 (S.D. Cal, 1989). affd, 951 F.2d 1128 (9″Cir. 1991), rev'd. 509 U.S. 579 (1993), on remand, 43 F.3d 1311 (9th Cir. 1995) (excluding Dr. Newman's testimony).
55. David TJ, Winder RM. 1985. Familial absence of the pectoralis major, serratus anterior, and latissimus dorsi muscles. J Med Genet 22:390-392.
56. David TJ. 1972. Dominant ectrodactyly and possible germinal mosaicism. J Med Genet 9:316-320.
57. David TJ. 1972. Familial Poland anomaly. J Med Genet 19:293-296.
58. Department of Health and Human Services (HHS). 1999a. Progestational drug products for human use: requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final Rule. Fed Reg 64:62110-62112.
59. Department of Health and Human Services. Health Resources and Services Administration. 2002. Public Health Service Act 42 CFR, Part 100, RIN 0906-AA55. Fed Reg 67, No. 143.
60. Depyper vs. Navarro, 1995. No. 83-303467-NM, 1995 WL 799928, *6.18.30,32 (Mich. Wayne Cty. Cir. Ct. 1995 aff'd, No. 191949 (Mich. Ct. App. Nov. 6, 1998).
61. Der Kaloustian VM, Hoyme HE, Hogg H, Entin MA, Guttmacher AE. 1991. Possible common pathogenetic mechanisms for Poland sequence and Adams-Oliver syndrome. Am J Med Genet 38:69-73.
62. Einarson TR, Leeder JS, Koren G. 1988. A method of meta-analysis of epidemiological studies. Drug Intell Clin Pharm 22:813-824.
63. Elbourne D, Mutch L, Campbell D, Campbell H, Samphie M. 1985. Debendox revisited. Br J Obstet Gynaecol 92:780-783.
64. Eskenazi B, Bracken MB. 1982. Bendectin (Debendox) as a risk factor for pyloric stenosis Am J Obstet Gynecol 144:919-924.
65. Federal Drug Administration. 1999a. Progestational drug products for human use; requirements for labeling directed to the patient. Fed Reg 64, No. 70, Proposed Rules, Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA), 21 CFR Part 310, [Docket No. 99N-0188], 64 FR 17985, DATE: Tuesday, April 13, 1999.
66. Federal Drug Administration. 1999b. Department of Health and Human Services. Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness. (Docket nos. 92F and 97-G437). Fed Reg 64:43190-43191.
67. Fleming DM, Knox JDE. 1981. Debendox in early pregnancy and fetal malformation. Br Med J 283:99-101.
68. Fuhrmann W, Mosseler U, Neuss H. 1971. [Clinical and genetic aspects of Poland's syndrome.] German. Dtsch Med Wochenschr 96:1076-1078.
69. General Practitioner Clinical Trials. 1963. Drugs in pregnancy survey. Practitioner 191:755-780.
70. Gibson GT, Colley DP, McMichael AJ, Hartshorne JM. 1981. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors. Med J Aust 1:410-414.
71. Golding J, Vivian S, Baldwin JA. 1983. Maternal anti-nauseants and clefts of lip and palate. Hum Toxicol 2:63-73.
72. Greenberg JH. 1982. Detection of teratogens by differentiating embryonic neural crest cells in culture: evaluation of a screening system. Teratog Carcinog Mutagen 2:319-323.
73. Guntakatta M, Matthews EJ, Rundell JO. 1984. Development of a mouse embryo limb bud cell culture system for the estimation of chemical teratogenic potential. Teratog Carcinog Mutagen 4:349-364.
74. Hagaman vs. Merrell Dow Pharmaceuticals, Inc. 1987. Civic Action No. 84-2202-S (d. Kansas 1987).
75. Harron DW, Griffiths K, Shanks RG. 1980. Debendox and congenital malformations in Northern Ireland. Br Med J 218:1379-1381.
76. Hassell JR, Horigan EA. 1982. Chondrogenesis: a model developmental system for measuring teratogenic potential of compounds. Teratog Carcinog Mutagen 2:325-331.
77. Hearey CD, Harris JA, Usatin MS, Epstein DM, Ury HK, Neutra RR. 1984. Investigation of a cluster of anencephaly and spina bifida. Am J Epidemiol 120:559-564.
78. Heinonen OP, Sloane D, Shapiro, S. 1977. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group, Inc.
79. Heinrichs L. 2002. Linking olfaction with nausea and vomiting of pregnancy, recurrent abortion, hyperemesis gravidarum, and migraine headache. Am J Obstet Gynecol 186(Suppl):215-219.
80. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. 1981. First trimester drug use and congenital disorders. JAMA 246:343-346. Correction in JAMA 246:2808.
81. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. 1981. First trimester drug use and congenital disorders. JAMA 246:343-346. Correction in JAMA 246:2808.
82. Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A. 2002. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol 186(Suppl):228-231.
83. Koren G, Levichek Z. 2002. The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. Am J Obstet Gynecol 186(Suppl):248-252.
84. Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and Birth defects II: ecological analyses. Teratology (in press).
85. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda Hideaki, Kuwaki T, Cao W-H, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M, Yazaki Y. 1994. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368:703-710.
86. Love MP, McMurray JJV. 1996. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 31:665-674.
87. MacKenzie HJ, Penrose LS. 1951. Two pedigrees of ectrodactyly. Ann Eugen 16:88-96.
88. Magee LA, Chandra K, Mazzotta P, Stewart D, Koren G, Guyatt GH. 2002a. Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. Am J Obstet Gynecol 186(Suppl):232-238.
89. Magee LA, Mazzotta P, Koren G. 2002b. Evidenced-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 186(Suppl):256-261.
90. Matteson S, Roscoe J, Hickok J, Morrow GR. 2002. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 186(Suppl):239-243.
91. McCredie J, Kricker A, Elliott J, Forest J. 1984. The innocent bystander: doxylamine/dicyclomine/pyridoxine and congenital limb defects. Med J Aust 140:525-527.
92. McCredie J, Kricker A. 1984. Debendox and pregnancy. Med J Aust 140 897-898.
93. McKeigue PM, Lamm SH, Linn S, Kutcher JS. 1994. Bendectin and birth defects I. Meta-analysis of the epidemiologic studies. Teratology 50:27-37.
94. McMullen G, Pearson K. 1913. On the inheritance of the deformity known as split foot or lobster claw. Biometrika 9:381-390.
95. Michaelis J, Gluck E. 1980. Teratogene Effekte Von Lenotan? (Does Lenotan Have Teratogenic Effects?) Dtsch Arzt 23:1527-1529.
96. Milkovich L, van den Berg BJ. 1976. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125:244-248.
97. Mitchell AA, Rosenberg L, Shapiro S, Slone D. 1981. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 245:2311-2314.
98. Mitchell AA, Shapiro S. 1983. Bendectin (Debendox) and congenital diaphragmatic hernia. Lancet 1:930.
99. Morelock S, Hingson R, Kayne H, Dooling E, Zuckerman B, Day N, Alpert JJ, Flowerdew G. 1982. Bendectin and fetal development. A study of Boston City Hospital. Am J Obstet Gynecol 142:209-213.
100. Muller L, Korte A, Madle S. 1989. Mutagenicity testing of doxylamine succinate, an anti-nauseant drug. Toxicol Lett 49:79-86.
101. Neugebauer H. 1962. [Spalthand und-fuss mit familaerer Besonderheit.] Z Orthop Ihre Grenzgeb 95:500-506.
102. Neutel CI. 2000. Variation in rates of hospitalization for excessive vomiting of pregnancy by Bendectin/Diclectin use in Canada. In: Koren G, Basahi R, editors. Nausea and vomiting of pregnancy: state of the art 2000. The First International Conference on Nausea and Vomiting of Pregnancy. Toronto: Motherisk. pp. 54-59.
103. Newman NM, Correy JF. 1977. A survey of congenital abnormalities and drugs in a private practice. Aust NZ J Obstet Gynaecol 17:156-159.
104. Niebyl JR, Goodwin TM. 2002. Overview of nausea and vomiting of pregnancy with an emphasis on vitamins and ginger. Am J Obstet Gynecol 186(Suppl):253-255.
105. Pearson KD. 1908. On inheritance of deformity known as split-food or lobster claw. Biometrika 6:69-79.
106. Pernow J, Wang Q-D. 1997. Endothelin in myocardial ischemia and reperfusion. Cardiovasc Res 33:518-526.
107. Roscoe JA, Matteson SE. 2002. Acupressure and acustimulation bands for control of nausea: A brief review. Am J Obstet Gynecol 186(Suppl): 244-247.
108. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg M. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 109:433-439.
109. Rudiger RA, Haase W, Passarge E. 1970. Association of ectrodactyly, ectodermal dysplasia, and cleft lip/palate. Am J Dis Child 120:160-163.
110. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 121:935-940.
111. Shapiro S, Heinonen OP, Siskind V, Kaufman DW, Mondson RR, Slone D. 1977. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Bendectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128:480-485.
112. Shiono PH, Klebanoff MA. 1989. Bendectin and human congenital malformations. Teratology, 40:151-155.
113. Simmon VF, Marx N. 1979. In vitro mutagenicity assays of five compounds of Bendectin. SRI International Project LSC-4442-30.
114. Smithells RW, Sheppard S. 1983. Teratogenicity of Debendox and pyrimethamine. Lancet 2:623-624.
115. Soltan HC, Holmes LB. 1986. Familial occurrence of malformations possibly attributable to vascular abnormalities. J Pediatr 108:112-114.
116. Steele VE, Morrissey RE, Elmore EL, Gurganus-Rocha D, Wilinson BP, Curren RD, Schmetter BS, Louie AT, Lamb JC, Yang LL. 1988. Evaluation of two in vitro assays to screen for potential developmental toxicants. Fundam Appl Toxicol 11:673-684.
117. Temtamy SA, McKusick VA. 1969. Synopsis of hand malformations with particular emphasis on genetic factors. Birth Defects Orig Artic Set V:125-184.
118. Wilson JG, Brent RL. 1981. Are female sex hormones teratogenic? Am J Obstet Gynecol 141:567-580.
119. Yerushalmy J, Milkovich L. 1965. Evaluation of the teratogenic effect of meclizine in man. Am J Obstet Gynecol 93:553-562.
120. Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 313:347-352.